- Home
- RVPHW vs SSBI Comparison
RVPHW vs SSBI Comparison
Compare RVPHW & SSBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- SSBI
- Stock Information
- Founded
- RVPHW N/A
- SSBI 1982
- Country
- RVPHW United States
- SSBI United States
- Employees
- RVPHW 15
- SSBI N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- SSBI Major Banks
- Sector
- RVPHW Health Care
- SSBI Finance
- Exchange
- RVPHW Nasdaq
- SSBI Nasdaq
- Market Cap
- RVPHW N/A
- SSBI N/A
- IPO Year
- RVPHW 2018
- SSBI 2006
- Fundamental
- Price
- RVPHW $0.14
- SSBI $7.10
- Analyst Decision
- RVPHW
- SSBI
- Analyst Count
- RVPHW 0
- SSBI 0
- Target Price
- RVPHW N/A
- SSBI N/A
- AVG Volume (30 Days)
- RVPHW N/A
- SSBI 10.1K
- Earning Date
- RVPHW N/A
- SSBI 01-28-2025
- Dividend Yield
- RVPHW N/A
- SSBI 3.92%
- EPS Growth
- RVPHW N/A
- SSBI N/A
- EPS
- RVPHW N/A
- SSBI 0.72
- Revenue
- RVPHW N/A
- SSBI $31,552,000.00
- Revenue This Year
- RVPHW N/A
- SSBI N/A
- Revenue Next Year
- RVPHW N/A
- SSBI N/A
- P/E Ratio
- RVPHW N/A
- SSBI $10.03
- Revenue Growth
- RVPHW N/A
- SSBI N/A
- 52 Week Low
- RVPHW N/A
- SSBI $5.68
- 52 Week High
- RVPHW N/A
- SSBI $12.87
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- SSBI 48.48
- Support Level
- RVPHW N/A
- SSBI $6.93
- Resistance Level
- RVPHW N/A
- SSBI $7.62
- Average True Range (ATR)
- RVPHW 0.00
- SSBI 0.29
- MACD
- RVPHW 0.00
- SSBI -0.02
- Stochastic Oscillator
- RVPHW 0.00
- SSBI 36.36
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.